Our Resources | Association for Accessible Medicines

COVID-19 and AAM - FAQ's and resources from the U.S. generics and biosimilars industry.

Mar 31, 2020 | Erica Klinger

AAM Letter to President on "Buy American" Requirements

Protective Mask - COVID-19

Mar 30, 2020 | Jeff Francer

COVID-19: This Week’s Initiatives From the Generic and Biosimilars Industry

Mar 24, 2020 | Rachel Schwartz

AAM Statement: Preserving Patient Access to Low-Cost Medicines Through COVID-19 and Beyond

Buy America Fact Sheet COVID-19

Mar 20, 2020 | Erica Klinger

AAM Buy American Fact Sheet

COVID-19 Response - Patient Access to Medicines

Mar 19, 2020 | Jeff Francer

AAM’s COVID-19 Response: Helping Patients and Families Meet Their Health Care Needs

Mar 18, 2020 | Joseph Stewart

Top 10 Ways to Commemorate the 10th Anniversary of Biosimilars in the U.S.

Coronavirus

Feb 28, 2020 | Jeff Francer

AAM Interim CEO Jeff Francer on COVID-19

Feb 28, 2020 | Erica Klinger

Stories and Data: How AAM Equips Advocates in the States

Feb 27, 2020 | Erik Komendant

The First (Price) Cut Is the Steepest

Feb 25, 2020 | Sara Skubikowski

Savings by Condition: The Latest Data

Feb 24, 2020 | Rachel Schwartz

AAM and the Biosimilars Council Applaud FDA’s Release of Enhanced Purple Book

Feb 20, 2020 | Craig Burton

White Paper: Medicare and Commercial Plans Fail to Get New Generics to Patients